ClinicalTrials.gg
RecruitingNCT05809986Updated Jul 7, 2026

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

An observational study in Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Recruiting at 10 sites in Portugal. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
174
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 23 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.

Planned enrollment
27th of 41
174 · median 312
Started
2023
with 7 others
Observational
41 of 106
7 open now
Primary completion
2026-12
later than 8 of 22 live
Registered
80th of 106
by date

Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 27th largest by planned enrollment of the 41 observational ones that give a count, is one of 8 that started in 2023, is one of 41 observational ones, reaches primary completion later than 8 of the 22 other live ones, and was the 80th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis by Novartis, or all of them as a file.
02

Study summary

This non-interventional study will compare the effect of Ofatumumab treatment between patients that began Ofatumumab within the 3 years after Multiple Sclerosis diagnosis and patients that began Ofatumumab with more than 3 years of Multiple Sclerosis diagnosis in a real-world setting in Portugal.

Read the detailed description

This is a 2 cohort, multi-center, observational study carried out in Portugal that aims to describe the effectiveness of Ofatumumab in a setting of routine medical care. Primary data will be collected from Multiple Sclerosis patients who initiate Ofatumumab early and later in their disease (cohorts 1 and 2, respectively).

Data will be collected during 3 visits distributed over a maximum period of 24 months. Exceptionally, if the patient shows Expanded Disability Status Scale (EDSS) worsening in visit 2 or 3 (12 and 24 months after Ofatumumab initiation, respectively), there will be an additional visit 6±1 months after visit 2 or 3 for EDSS confirmation.

The study includes patients that have initiated Ofatumumab up to 12 months prior inclusion in the study OR Patients that are initiating Ofatumumab at the moment of study inclusion.

Patients in both cohorts will have to be treated with Ofatumumab for at least two years to compare No Evidence of Disease Activity (NEDA)-3 at 12 to 24 months, respectively.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing Multiple Sclerosis
  • RMS
  • Ofatumumab
  • NIS
  • Portugal
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include male and female patients (aged ≥ 18 years) with a documented diagnosis of RMS and with Ofatumumab treatment in line with the Portuguese label i.e., adult patients with active, relapsing forms of MS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To participate in the study, all the following inclusion criteria must be met:

  • Patients aged 18 years or older
  • Written obtained before participating in the study.
  • Patient is willing and able to complete the assessments, including PRO questionnaires, as outlined in this study.
  • Diagnosis of RMS per McDonald Criteria (2017) occurred prior to initiation of Ofatumumab.
  • Treatment with Ofatumumab is in accordance with the Portuguese indication of Kesimpta® (i.e., treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features).
  • Patients that have initiated Ofatumumab up to 12 M prior inclusion in the study OR Patients that are initiating Ofatumumab at the moment of study inclusion.

Exclusion criteria

Exclusion Criteria:

To participate in the study, none of the following exclusion criteria must be met:

  • Use of drugs during the study, OR between Ofatumumab initiation and inclusion into the study, OR within 5 half-lives of investigational drug before Ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
  • Use of high efficacy therapy (including Ocrelizumab, Natalizumab, Mitoxantrone, Rituximab and Alemtuzumab) in both cohorts prior to the initiation of Ofatumumab.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
174 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Early treatment arm

    All patients who initiated Ofatumumab within 3 years after MS diagnosis (can be treatment-naive or switch).

    Other: Ofatumumab

  • Cohort 2: Late treatment arm

    All patients who initiated Ofatumumab with more than 3 years of MS diagnosis.

    Other: Ofatumumab

Interventions

  • OtherOfatumumab

    There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

    Also known as: Kesimpta

06

What researchers measure

Primary outcomes

  1. Proportion of patients demonstrating NEDA-3

    Proportion of patients demonstrating No Evidence of Disease Activity (NEDA)-3 (12-24 months) in both cohorts, respectively. NEDA-3 is defined by no confirmed Multiple Sclerosis relapse, no new or enlarging T2 lesions, no Gadolinium-positive T1 lesions, and no six-month confirmed disability worsening.

    Time frame: from month 12 up to month 24

Secondary outcomes

  1. Proportion of patients demonstrating no evidence of disease activity in individual components of NEDA-3

    Proportion of patients demonstrating no evidence of disease activity in individual components of NEDA-3 (12-24 months) in the overall population and in both cohorts.

    Time frame: 12-24 months

  2. Multiple Sclerosis Impact Scale Questionnaire (MSIS-29)

    Treatment effect of Ofatumumab on the impact of multiple sclerosis as measured by MSIS-29 (baseline, 12 and 24 months) in the overall population and in both cohorts. MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 4 response options. Each score domain is obtained by summing all individual items and transformed it to a -100 scale where high scores indicate worse health.

    Time frame: Baseline, Month 12, Month 24

  3. Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS)

    Treatment effect of Ofatumumab on the impact of multiple sclerosis as measured by FSIQ-RMS (baseline, 12 and 24 months) in the overall population and in both cohorts. The FSIQ-RMS is a patient-reported outcome (PRO) instrument used to assess fatigue in patients with relapsing types of multiple sclerosis (RMS).It is a 20-item self-report measure with 7 items for MS-related symptoms of fatigue and 13 for fatigue-related impacts on several aspects of patients' lives. The impact of fatigue divides into 3 subdomains: physical, cognitive and emotional, and coping. The scores for fatigue and the subdomains of impact are standardized to a 0-100 scale using a scoring algorithm, with higher scores indicating more severe symptoms and impacts.

    Time frame: Baseline, Month 12, Month 24

  4. Treatment Satisfaction Questionnaire for Multiple Sclerosis (TSQM-9)

    Treatment satisfaction with Ofatumumab as measured by TSQM-9 (baseline, 12 and 24 months) in the overall population and in both cohorts. The TSQM-9 is a validated tool, widely used, to measure treatment satisfaction that will be applied in the context of this study regarding Ofatumumab. The TSQM-9 uses nine of the 14 TSQM Version 1.4 items, not including five questions related to side effects of medication, and comprises three scales: the effectiveness scale, the convenience scale and the global scale. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.

    Time frame: Month 12, Month 24

  5. Proportion of patients permanently discontinuing Ofatumumab during the study

    Proportion of patients permanently discontinuing Ofatumumab during the study, and reasons for discontinuation in the overall population and in both cohorts

    Time frame: up to month 24

  6. Proportion of patients demonstrating NEDA-3 in the overall population.

    Proportion of patients demonstrating NEDA-3 in the overall population.

    Time frame: 12-24 months

07

Study locations

10 of 10 sites recruiting
  • Novartis Investigative Site
    Amadora, 2720-276, Portugal
    Recruiting
  • Novartis Investigative Site
    Guimarães, 4835-044, Portugal
    Recruiting
  • Novartis Investigative Site
    Leiria, 2410-197, Portugal
    Recruiting
  • Novartis Investigative Site
    Lisbon, 1169-050, Portugal
    Recruiting
  • Novartis Investigative Site
    Lisbon, 1349-019, Portugal
    Recruiting
  • Novartis Investigative Site
    Lisbon, 1649-035, Portugal
    Recruiting
  • Novartis Investigative Site
    Matosinhos Municipality, 4454-513, Portugal
    Recruiting
  • Novartis Investigative Site
    Ponte de Lima, 4990-041, Portugal
    Recruiting
  • Novartis Investigative Site
    Porto, 4200 319, Portugal
    Recruiting
  • Novartis Investigative Site
    Setúbal, 2910-549, Portugal
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 37 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
Apr 12, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05809986
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
Nov 27, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion